Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine Gel for Uncomplicated Cutaneous Leishmaniasis
NCT07149753Phase 1Not yet recruiting
- Sponsor
- Universidad Industrial de Santander
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of miltefosine in cutaneous leishmaniasis (CL) (3 arms), sponsored by Universidad Industrial de Santander. Primary endpoint: End of treatment lesion healing at 28 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
miltefosine
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT07149753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07149753.